The purpose of the research study is to determine the response rates when Revlimid® is
combined with Doxil® and Dexamethasone (Dd-R) in newly diagnosed Multiple Myeloma. The study
will also evaluate the side effects caused by the combination of these three drugs. This
therapy is investigational in the treatment of Multiple Myeloma.
Revlimid® is a drug that alters the immune system and it may also interfere with the
development of tiny blood vessels that help support tumor growth. Therefore, in theory, it
may reduce or prevent the growth of cancer cells. Revlimid® is approved by the Food and Drug
Administration (FDA) for specific types of myelodysplastic syndrome (MDS) and Multiple
Myeloma, two different types of blood cancer. It is currently being tested in a variety of
other cancer conditions. In this case it is considered experimental.
Doxil® is a form of chemotherapy. It is approved by the FDA for the treatment of relapsed/
refractory Multiple Myeloma in combination with Velcade.
Dexamethasone is a steroid. It is also approved by the FDA, but not for the treatment of
Multiple Myeloma. It is considered a standard part of most myeloma therapies for newly
diagnosed patients.
Phase:
Phase 2
Details
Lead Sponsor:
H. Lee Moffitt Cancer Center and Research Institute